Cargando…
Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX
Several studies have reported that the prognostic effect of KRAS mutations on colorectal cancers (CRCs) varies depending on the type of mutation. Considering the effect of KRAS mutations on tumor microenvironment, we analyzed the prognostic significance of KRAS mutation types after adjusting for the...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285533/ https://www.ncbi.nlm.nih.gov/pubmed/34272423 http://dx.doi.org/10.1038/s41598-021-94044-4 |
_version_ | 1783723578052575232 |
---|---|
author | Park, Hye Eun Yoo, Seung-Yeon Cho, Nam-Yun Bae, Jeong Mo Han, Sae-Won Lee, Hye Seung Park, Kyu Joo Kim, Tae-You Kang, Gyeong Hoon |
author_facet | Park, Hye Eun Yoo, Seung-Yeon Cho, Nam-Yun Bae, Jeong Mo Han, Sae-Won Lee, Hye Seung Park, Kyu Joo Kim, Tae-You Kang, Gyeong Hoon |
author_sort | Park, Hye Eun |
collection | PubMed |
description | Several studies have reported that the prognostic effect of KRAS mutations on colorectal cancers (CRCs) varies depending on the type of mutation. Considering the effect of KRAS mutations on tumor microenvironment, we analyzed the prognostic significance of KRAS mutation types after adjusting for the tumor-infiltrating lymphocytes (TIL) and tumor-stromal percentage (TSP) statuses. In two independent cohorts, KRAS mutations were analyzed by Sanger sequencing and/or next-generation sequencing. TIL density and the TSP were quantified from whole-slide immunohistochemical images. KRAS-mutant CRCs were divided into three subgroups (G12D/V, other codon 12 mutations and codon 13 mutations) to examine their differential effect on TIL density, the TSP and recurrence-free survival (RFS). Among the KRAS mutations, only the G12D/V subgroups showed significantly less TIL infiltration than the wild-type CRCs. According to survival analysis, G12D/V mutations were associated with short RFS; codon 13 mutations showed discordant trends in the two cohorts, and other codon 12 mutations showed no significant association. Multivariate analysis further supported the prognostic value of G12D/V mutations. This result is not only consistent with a recent study suggesting the immunosuppressive effect of mutant KRAS but also provides insight into the type-specific prognostic effect of KRAS mutations. |
format | Online Article Text |
id | pubmed-8285533 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-82855332021-07-21 Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX Park, Hye Eun Yoo, Seung-Yeon Cho, Nam-Yun Bae, Jeong Mo Han, Sae-Won Lee, Hye Seung Park, Kyu Joo Kim, Tae-You Kang, Gyeong Hoon Sci Rep Article Several studies have reported that the prognostic effect of KRAS mutations on colorectal cancers (CRCs) varies depending on the type of mutation. Considering the effect of KRAS mutations on tumor microenvironment, we analyzed the prognostic significance of KRAS mutation types after adjusting for the tumor-infiltrating lymphocytes (TIL) and tumor-stromal percentage (TSP) statuses. In two independent cohorts, KRAS mutations were analyzed by Sanger sequencing and/or next-generation sequencing. TIL density and the TSP were quantified from whole-slide immunohistochemical images. KRAS-mutant CRCs were divided into three subgroups (G12D/V, other codon 12 mutations and codon 13 mutations) to examine their differential effect on TIL density, the TSP and recurrence-free survival (RFS). Among the KRAS mutations, only the G12D/V subgroups showed significantly less TIL infiltration than the wild-type CRCs. According to survival analysis, G12D/V mutations were associated with short RFS; codon 13 mutations showed discordant trends in the two cohorts, and other codon 12 mutations showed no significant association. Multivariate analysis further supported the prognostic value of G12D/V mutations. This result is not only consistent with a recent study suggesting the immunosuppressive effect of mutant KRAS but also provides insight into the type-specific prognostic effect of KRAS mutations. Nature Publishing Group UK 2021-07-16 /pmc/articles/PMC8285533/ /pubmed/34272423 http://dx.doi.org/10.1038/s41598-021-94044-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Park, Hye Eun Yoo, Seung-Yeon Cho, Nam-Yun Bae, Jeong Mo Han, Sae-Won Lee, Hye Seung Park, Kyu Joo Kim, Tae-You Kang, Gyeong Hoon Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX |
title | Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX |
title_full | Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX |
title_fullStr | Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX |
title_full_unstemmed | Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX |
title_short | Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX |
title_sort | tumor microenvironment-adjusted prognostic implications of the kras mutation subtype in patients with stage iii colorectal cancer treated with adjuvant folfox |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285533/ https://www.ncbi.nlm.nih.gov/pubmed/34272423 http://dx.doi.org/10.1038/s41598-021-94044-4 |
work_keys_str_mv | AT parkhyeeun tumormicroenvironmentadjustedprognosticimplicationsofthekrasmutationsubtypeinpatientswithstageiiicolorectalcancertreatedwithadjuvantfolfox AT yooseungyeon tumormicroenvironmentadjustedprognosticimplicationsofthekrasmutationsubtypeinpatientswithstageiiicolorectalcancertreatedwithadjuvantfolfox AT chonamyun tumormicroenvironmentadjustedprognosticimplicationsofthekrasmutationsubtypeinpatientswithstageiiicolorectalcancertreatedwithadjuvantfolfox AT baejeongmo tumormicroenvironmentadjustedprognosticimplicationsofthekrasmutationsubtypeinpatientswithstageiiicolorectalcancertreatedwithadjuvantfolfox AT hansaewon tumormicroenvironmentadjustedprognosticimplicationsofthekrasmutationsubtypeinpatientswithstageiiicolorectalcancertreatedwithadjuvantfolfox AT leehyeseung tumormicroenvironmentadjustedprognosticimplicationsofthekrasmutationsubtypeinpatientswithstageiiicolorectalcancertreatedwithadjuvantfolfox AT parkkyujoo tumormicroenvironmentadjustedprognosticimplicationsofthekrasmutationsubtypeinpatientswithstageiiicolorectalcancertreatedwithadjuvantfolfox AT kimtaeyou tumormicroenvironmentadjustedprognosticimplicationsofthekrasmutationsubtypeinpatientswithstageiiicolorectalcancertreatedwithadjuvantfolfox AT kanggyeonghoon tumormicroenvironmentadjustedprognosticimplicationsofthekrasmutationsubtypeinpatientswithstageiiicolorectalcancertreatedwithadjuvantfolfox |